Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $4.9 million.

  • Stoke Therapeutics' Change in Accured Expenses rose 75166.89% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 616916.67%. This contributed to the annual value of $3.1 million for FY2024, which is 19625.94% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Change in Accured Expenses of $4.9 million as of Q3 2025, which was up 75166.89% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Change in Accured Expenses registered a high of $4.9 million during Q3 2025, and its lowest value of -$4.4 million during Q2 2023.
  • For the 4-year period, Stoke Therapeutics' Change in Accured Expenses averaged around $582466.7, with its median value being $351000.0 (2023).
  • In the last 5 years, Stoke Therapeutics' Change in Accured Expenses crashed by 67738.69% in 2023 and then surged by 75166.89% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Change in Accured Expenses (Quarter) stood at $199000.0 in 2022, then crashed by 677.39% to -$1.1 million in 2023, then soared by 289.64% to $2.2 million in 2024, then skyrocketed by 124.0% to $4.9 million in 2025.
  • Its Change in Accured Expenses stands at $4.9 million for Q3 2025, versus $2.8 million for Q2 2025 and $4.7 million for Q1 2025.